← All Conditions

Ibogaine for Alcohol Use Disorder: What Research Shows

What animal studies, one small human pilot, and early noribogaine trials do and do not tell us about ibogaine for alcohol use disorder.

Last reviewed: November 10, 2026By: Ibogaine Treatment Guide Editorial Team9 peer-reviewed sources citedEditorial policy

What Alcohol Use Disorder Is and Who It Affects

Alcohol use disorder (AUD) is a medical condition in which a person has trouble stopping or controlling their drinking even though it is harming their health, relationships or work. Clinicians diagnose it using DSM-5 criteria and grade it as mild, moderate or severe depending on how many criteria are met. Older terms such as alcoholism and alcohol dependence describe the more severe end of the same range.

AUD is one of the most common health conditions in the United States. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) reports these figures from the 2024 National Survey on Drug Use and Health:

  • 27.9 million people aged 12 and older (9.7%) had AUD in the past year
  • about 16.7 million males and 11.2 million females were affected
  • about 775,000 adolescents aged 12 to 17 met the criteria

Most people with AUD never get care for it. According to NIAAA, only 7.6% of people with past-year AUD received any alcohol treatment in 2024, and only about 2.5% received medication for it.

Alcohol withdrawal is a separate and serious concern. Up to half of people with a long history of heavy drinking develop withdrawal symptoms when they cut back sharply or stop. In its most severe form, which includes seizures and delirium tremens, withdrawal can be life-threatening (Day & Daly, 2022). This matters a great deal for anyone considering ibogaine, as the safety section explains.

This page is educational information, not medical advice. Ibogaine is a Schedule I controlled substance in the United States, and the FDA has not approved it for any condition.

Current Evidence-Based Treatments and Their Outcomes

AUD is treatable, and randomized controlled trials support several approaches. Treatment works best when it is matched to the person and continued over time.

Medically managed withdrawal. For people at risk of significant withdrawal, supervised detoxification is often the first step. Benzodiazepines are the best-studied medications for preventing severe withdrawal complications, although they carry their own risks. A 2022 clinical review in Addiction describes withdrawal management as the start of a longer treatment journey, not a treatment on its own (Day & Daly, 2022).

Medications for AUD. A 2014 JAMA systematic review and meta-analysis covered 122 randomized trials and one cohort study, with about 22,800 participants in total (Jonas et al., 2014). It found:

  • Acamprosate: 12 people needed treatment to prevent one return to any drinking (the number needed to treat, or NNT)
  • Oral naltrexone (50 mg/day): an NNT of 20 to prevent a return to any drinking, and 12 to prevent a return to heavy drinking
  • no statistically significant difference between acamprosate and naltrexone when the two were compared directly
  • fewer heavy drinking days with injectable naltrexone
  • moderate evidence that topiramate and nalmefene improve some drinking outcomes

These benefits are modest, but they come from large controlled datasets, which is the kind of evidence ibogaine does not yet have. About 1 in 48 patients taking naltrexone left trials because of side effects. Acamprosate did not significantly increase dropout due to adverse events (Jonas et al., 2014).

Behavioral and psychosocial care. Counseling, relapse-prevention planning, mutual-help groups and family-involved care are standard parts of AUD treatment and are often combined with medication.

There is a large gap between what works and what people actually receive. Only about 1 in 40 people with AUD in the US received medication for it in 2024 (NIAAA). Widening access to these established treatments is a major public health priority in its own right.

Why Researchers Are Studying Ibogaine for Alcohol Use Disorder

Ibogaine is an alkaloid from the root bark of Tabernanthe iboga, a shrub from West Central Africa. Most interest in ibogaine for addiction has focused on opioids, but laboratory studies have also examined alcohol.

The GDNF hypothesis. The most-cited work on how ibogaine might affect alcohol drinking comes from Dorit Ron's laboratory at UCSF. In a 2005 Journal of Neuroscience study in Long-Evans rats, He and colleagues found that:

  • ibogaine (40 mg/kg) reduced alcohol intake in two-bottle choice tests, in operant self-administration tests (where rats work for alcohol), and in a relapse model, without reducing the rats' preference for sugar water
  • injecting ibogaine directly into the ventral tegmental area (VTA), a midbrain reward region, reduced alcohol self-administration for up to 48 hours
  • ibogaine given throughout the body increased midbrain expression of glial cell line-derived neurotrophic factor (GDNF) in rats and mice
  • injecting GDNF into the VTA reproduced ibogaine's effect, and blocking GDNF with antibodies weakened it

The authors concluded that GDNF in the VTA drives ibogaine's effect on alcohol drinking in these rodents.

Noribogaine. The body converts ibogaine into noribogaine, a long-acting metabolite. A 2010 follow-up from the same group compared it with ibogaine and with a related compound, 18-MC (Carnicella et al., 2010). Like ibogaine, noribogaine raised GDNF mRNA in a human neuroblastoma cell line and reduced operant alcohol responding when infused into the rat VTA. 18-MC did neither.

Evidence level. These are animal and cell studies. They point to a plausible biological pathway, but rodent drinking models often fail to predict results in people, and none of this work shows that ibogaine reduces drinking in humans. Ibogaine also acts on several other targets, including potassium channels in the heart (Koenig & Hilber, 2015). Which of these targets matter for alcohol in people, if any, is unknown.

What Human Research on Ibogaine for Alcohol Use Disorder Shows

Evidence level: no randomized controlled trials of ibogaine for alcohol use disorder have been published. The human evidence consists of one small open-label pilot study plus scattered case reports.

The São Paulo pilot study (2026). The most relevant human data come from researchers at the University of São Paulo's Ribeirão Preto Medical School. They published their results in 2026 in Trends in Psychiatry and Psychotherapy (Rocha et al., 2026), and the trial is registered as NCT03380728. Key features:

  • nine adults with moderate to severe AUD who had at least two previous failed treatments
  • admission to hospital 24 to 48 hours before dosing, with continuous monitoring
  • oral ibogaine hydrochloride, given in escalating doses (20 mg up to 320 mg) to the first three volunteers and as a single 400 mg dose to the other six
  • exclusion of people with cardiovascular or liver disease, and of people with a personal or family history of bipolar or psychotic disorders

What it found. Most participants reported drinking less. However, only five of the nine completed the study, and the published abstract does not give detailed drinking or craving data. There were no serious adverse events. Drowsiness, nausea and anxiety were common at doses of 240 to 400 mg, and two patients needed medication for agitation, insomnia and high blood pressure. Five of the nine participants had QTc changes, including both temporary prolongation and shortening, and blood pressure changes were also seen.

The authors concluded that moderate doses of ibogaine showed cardiotoxic potential, which calls for rigorous cardiovascular screening and continuous monitoring. They also said randomized controlled trials are needed to confirm whether it works.

What this study does not show. With nine participants, no control group and no blinding, the study cannot separate an ibogaine effect from motivation, the effect of being in hospital, expectation, or natural ups and downs in drinking. It was designed to test feasibility and safety, not effectiveness.

Clinic and personal reports. Clinics outside the US treat people for alcohol problems, and personal accounts are widely shared. These reports are not collected systematically and rarely include long-term follow-up. They are also prone to selection bias, because people with poor outcomes are less likely to share their stories. For these reasons, they cannot establish that ibogaine is effective or safe.

Noribogaine and the DMX-1001 Trial Program

Ibogaine's heart effects and long, intense psychoactive experience limit its use, so some developers are working on related compounds.

DMX-1001 is an oral form of noribogaine that the company DemeRx is developing for alcohol use disorder. The company's April 2026 announcement said:

  • the FDA accepted an Investigational New Drug (IND) application for DMX-1001 in AUD
  • a multiple ascending dose study in healthy volunteers has been completed, and the company reports that its safety and tolerability results support further development
  • the company expects a Phase 2 trial in people with AUD to start in 2027, once a planned alcohol interaction trial is successfully completed

Evidence level: no efficacy data for DMX-1001 in people with AUD have been reported. The safety information so far comes from company press releases, not peer-reviewed publications.

Noribogaine is not free of cardiac concerns either. A 2015 review notes that both ibogaine and noribogaine inhibit hERG potassium channels in the heart, the mechanism linked to QT prolongation (Koenig & Hilber, 2015). When noribogaine results do appear, they will not automatically apply to ibogaine as given in clinics, which has different effects and duration.

What Medically Supervised Ibogaine Administration Involves

In the United States, ibogaine is not legally available for treatment outside approved research. People who seek it usually travel to clinics in countries where it is unregulated or tolerated, and practices vary widely. The São Paulo research protocol and the safety literature point to several elements that careful programs generally include:

  • medical and psychiatric screening: a full history, a physical exam, and a review of all medications and supplements
  • a baseline ECG to measure the QT interval, with exclusion of people who have heart disease
  • blood tests, typically including electrolytes and liver function, which are especially relevant after heavy drinking
  • confirmation that alcohol withdrawal is complete before dosing, with a period of observed abstinence (the São Paulo pilot admitted participants 24 to 48 hours before dosing)
  • continuous cardiac monitoring during dosing and for an extended period afterward, with staff trained in advanced cardiac life support, a defibrillator on site, and a plan for transfer to hospital
  • aftercare: ongoing counseling, relapse-prevention planning and, where appropriate, connection to standard AUD medication

The acute experience lasts many hours. In the São Paulo pilot it brought drowsiness, nausea and anxiety, and some participants needed treatment for agitation and high blood pressure (Rocha et al., 2026). Ibogaine is not a stand-alone cure. Where researchers discuss possible benefits, they generally frame them as an opening for engaging with longer-term care.

It is reasonable to ask any clinic how it screens and monitors patients and what it does in an emergency. A clinic's marketing is not evidence that its treatment works.

Ibogaine and Alcohol: Safety, Cardiac Risk and Contraindications

People have died during or after ibogaine treatment, both in clinics with medical staff and outside them. A forensic review of known deaths between 1990 and 2008 identified 19 people who died 1.5 to 76 hours after taking ibogaine. Of the 14 cases with adequate postmortem data, 12 had pre-existing medical conditions (mostly cardiovascular), other substances, or both, that explained or contributed to the death (Alper et al., 2012).

Cardiac risk (QT prolongation). Ibogaine and noribogaine block hERG potassium channels. This slows the heart's electrical recovery after each beat and prolongs the QT interval, which can lead to a dangerous arrhythmia called torsade de pointes and to sudden cardiac death (Koenig & Hilber, 2015). Reported QT prolongation has lasted more than 24 hours after dosing, so the risk does not end when the acute effects fade. Even in the carefully screened São Paulo pilot, five of nine participants had QTc changes (Rocha et al., 2026). Continuous ECG monitoring can catch a dangerous rhythm early enough to treat it, but it does not prevent arrhythmias and it can miss them.

Alcohol withdrawal is a specific danger. The same forensic review identified seizures associated with withdrawal from alcohol and benzodiazepines as an apparent risk factor in ibogaine-associated deaths (Alper et al., 2012). Ibogaine is not a treatment for alcohol withdrawal. Anyone physically dependent on alcohol needs medically managed withdrawal first, because severe withdrawal can cause seizures and delirium tremens on its own (Day & Daly, 2022). Stopping drinking abruptly without medical supervision to prepare for a clinic can be dangerous.

Contraindications and red flags that research protocols and the safety literature commonly cite include:

  • known heart disease, arrhythmia, or a prolonged QTc on ECG
  • a personal or family history of long QT syndrome or unexplained sudden cardiac death
  • significant liver disease, which is common after long-term heavy drinking (the São Paulo trial excluded hepatic disease)
  • active alcohol withdrawal, or recent heavy drinking without a completed detox
  • current use of medications that prolong the QT interval
  • a personal or family history of psychotic or bipolar disorders
  • pregnancy or breastfeeding

Opioid use. Some people with AUD also use opioids. Opioid tolerance falls after ibogaine treatment by an amount no one can predict, so a dose used before can be a fatal overdose: leave treatment with naloxone, and call emergency services if an overdose is suspected.

This information is educational, not medical advice. Ibogaine is a Schedule I substance in the US. Make decisions about AUD treatment with a qualified clinician.

Open Questions and Research Gaps

Several important questions remain unanswered:

  • Does ibogaine reduce drinking in people at all? No controlled trial has tested this. The only published human study had nine participants and no control group.
  • How long would any effect last? The rodent effects were measured over hours to days. How long any effect lasts in humans is unknown.
  • Does the GDNF mechanism apply to humans? It has been shown in rats, mice and cell lines, not in people.
  • Is there a safe dose for people with AUD? The São Paulo authors found cardiotoxic potential at moderate doses. Long-term heavy drinking can affect the heart and liver, which may change the risk in ways that have not been studied.
  • How does ibogaine compare with naltrexone or acamprosate? No head-to-head studies exist, so claims that ibogaine outperforms established AUD medications are not supported by evidence.
  • Will noribogaine (DMX-1001) work? Phase 2 testing in people with AUD has not started. The company projects a 2027 start.

Until randomized controlled trials report results, ibogaine for alcohol use disorder remains an experimental approach with documented serious risks and unproven benefit. Established treatments, including FDA-approved medications and behavioral therapies, have far stronger evidence.

Frequently Asked Questions

Does ibogaine work for alcohol use disorder?

This has not been established. Ibogaine reduced alcohol drinking in rat studies, but the only published human study of alcohol use disorder was a 2026 open-label pilot with nine participants and no control group. Most participants reported drinking less, but only five completed the study, and five had heart rhythm (QTc) changes. The authors themselves said randomized controlled trials are needed to confirm whether it works.

Does ibogaine work for alcohol cravings?

There is no reliable human evidence that ibogaine reduces alcohol cravings. Rodent studies show reduced alcohol drinking and reduced drinking in a relapse model, possibly through the brain growth factor GDNF. The 2026 human pilot did not report detailed craving data in its abstract. Personal reports of reduced craving exist but are uncontrolled. Naltrexone and acamprosate have far stronger trial evidence for reducing drinking.

Is ibogaine safe during alcohol withdrawal?

No. A forensic review of ibogaine-associated deaths identified seizures linked to withdrawal from alcohol and benzodiazepines as an apparent risk factor. Ibogaine does not treat alcohol withdrawal, and severe withdrawal can cause seizures and delirium tremens on its own. People who are physically dependent on alcohol need medically managed withdrawal before any other treatment is considered. Stopping abruptly without supervision can be dangerous.

How does ibogaine compare with naltrexone for alcohol?

No studies have compared them directly. Naltrexone is FDA-approved, and a large 2014 JAMA meta-analysis of randomized trials found it reduces returns to heavy drinking, with an established safety profile. Ibogaine has no randomized trials in alcohol use disorder, carries serious cardiac risks, and is a Schedule I substance in the US. The evidence for the two treatments is not comparable in size or quality.

What is DMX-1001 and is there a noribogaine trial for alcohol use disorder?

DMX-1001 is an oral form of noribogaine, ibogaine's main metabolite, developed by DemeRx. In April 2026 the company announced that the FDA had accepted its Investigational New Drug application for alcohol use disorder. It has completed a dosing study in healthy volunteers and expects a Phase 2 trial in people with AUD to start in 2027, after an alcohol interaction study. No efficacy results in AUD exist yet.

What are the heart risks of ibogaine?

Ibogaine and its metabolite noribogaine block hERG potassium channels in the heart, which can prolong the QT interval and trigger a dangerous arrhythmia called torsade de pointes. QT prolongation has been reported to last more than 24 hours. In the 2026 alcohol pilot, five of nine screened participants had QTc changes. ECG monitoring can catch problems early enough to treat them, but it does not prevent them.

Is ibogaine legal for treating alcoholism in the United States?

No. Ibogaine is a Schedule I controlled substance in the United States, and the FDA has not approved it for alcohol use disorder or any other condition. In the US it can only be given in authorized research. People who seek it usually travel to clinics in other countries, where regulation and medical standards vary widely.

What should I ask an ibogaine clinic for alcoholism?

Ask how the clinic screens for heart and liver problems, whether it requires a baseline ECG and blood tests, and how it confirms that alcohol withdrawal is complete before dosing. Ask what cardiac monitoring it uses and for how long, whether staff are trained in advanced cardiac life support, how far away the nearest hospital is, and what aftercare it provides. Marketing claims are not evidence of effectiveness.